The Alabama Medical Cannabis Commission, at its meeting Feb. 13, 2025, approved an offering of State Testing Laboratory Licenses to commence on Feb. 14. Those interested in applying for a State Testing Laboratory license must file a Request for Business Application through the AMCC application portal.

“Despite some delays, we are excited to see the progress that’s being made in Alabama’s medical cannabis industry,” said Director John McMillan. “There are several licensed cultivators who are growing and harvesting legal cannabis in Alabama, and this offering of state testing laboratory licenses is critical to move those crops through the process and, ultimately, into the hands of Alabama patients.”

Only applicants who submit a Request for Business Application by March 14, will receive a Business Application Form. The Business Application Forms and accompanying application instructions will issue to requestors on March 17, and applicants will have until April 16, to file an application.

The Commission will review and evaluate all timely and properly filed applications and award licenses in this offering on June 17. There is no statutory limit on the number of State Testing Laboratory licenses the Commission may award.

“The primary objective of the Commission has always been helping Alabama patients through access to the benefits of medical cannabis products,” explained Commission Chairman Rex Vaughn. “Delivering on that objective is possible only if we have licensed state testing laboratories to ensure those products are safe and satisfy the requirements of Alabama law.”

Under Alabama’s program, registered certifying physicians may recommend medical cannabis to patients who have been diagnosed with autism spectrum disorder; cancer-related pain or nausea; Crohn’s Disease; depression; epilepsy or conditions causing seizures; HIV/AIDS-related nausea or weight loss; panic disorder; Parkinson’s Disease; persistent nausea; post-traumatic stress disorder; sickle cell anemia; spasticity associated with multiple sclerosis or spinal cord injury; Tourette’s Syndrome; a terminal illness; or conditions causing chronic or intractable pain.

Medical cannabis products that may be recommended to patients include tablets, capsules, tinctures, gelatinous cubes, gels, oils or creams for topical use, suppositories, transdermal patches, nebulizers, or liquids or oils for use in an inhaler. Raw plant materials, products administered by smoking or vaping, or food products such as cookies or candies will not be allowed.

To learn more about the Alabama medical cannabis program or to file a Request for Business Application visit amcc.alabama.gov/cannabis-business-applicants.